MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 4, 2008, Pages 1285-1290

  Jinushi, Masahisa ^a,b   Vanneman, Matthew ^a,b   Munshi, Nikhil C ^a,b   Tai, Yu Tzu ^a,b   Prabhala, Rao H ^a,b   Ritz, Jerome ^a,b   Neuberg, Donna ^c   Anderson, Kenneth C ^a,b   Carrasco, Daniel Ruben ^a,b   Dranoff, Glenn ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ERp5; MICA; NKG2D; Plasma cell; Tumor immunity

Indexed keywords

ANTIBODY; BORTEZOMIB; DEXAMETHASONE; ERP5 PROTEIN; MEMBRANE RECEPTOR; MHC CLASS 1 CHAIN RELATED PROTEIN A; MHC CLASS 1 CHAIN RELATED PROTEIN A ANTIBODY; NATURAL KILLER CELL RECEPTOR NKG2D; PROTEIN DISULFIDE ISOMERASE; UNCLASSIFIED DRUG; ALLOANTIBODY; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; HLA ANTIGEN CLASS 1; LIGAND; MHC CLASS I RELATED CHAIN A; MHC CLASS I-RELATED CHAIN A; PYRAZINE DERIVATIVE;

CD8+ T LYMPHOCYTE; CONFERENCE PAPER; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXICITY; DENDRITIC CELL; DNA DAMAGE; DOWN REGULATION; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NATURAL KILLER CELL; OPSONIZATION; PATHOGENESIS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; ARTICLE; BIOSYNTHESIS; CELL CULTURE; DISEASE COURSE; IMMUNOLOGY; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CROSS-PRIMING; DENDRITIC CELLS; DISEASE PROGRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; ISOANTIBODIES; LIGANDS; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; TUMOR CELLS, CULTURED;

EID: 39549084084     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0711293105     Document Type: Article

References (51)

1. Kyle RA, et al. (2006) Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354:1362-1369.
2. Kyle RA, et al. (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564-569.
3. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 121:749-757.
4. Davies FE, et al. (2003) Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 102:4504-4511.
5. Kuehl WM, Bergsagel PL (2002) Multiple myeloma: Evolving genetic events and host interactions. Nat Rev Cancer 2:175-187.
6. Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23:6333-6338.
7. Carrasco DR, et al. (2006) High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9:313-325.
8. Reimold AM, et al. (2001) Plasma cell differentiation requires the transcription factor XBP-1. Nature 412:300-307.
9. Iwakoshi NN, et al. (2003) Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol 4:321-329.
10. Carrasco DR, et al. (2007) The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11:349-360.
11. Kukreja A, et al. (2006) Enhancement of clonogenicity of human multiple myeloma by dendritic cells. J Exp Med 203:1859-1865.
12. Prabhala RH, et al. (2006) Dysfunctional T regulatory cells in multiple myeloma. Blood 107:301-304.
13. Dhodapkar MV, Krasovsky J, Osman K, Geller MD (2003) Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy. J Exp Med 198:1753-1757.
14. Dranoff G (2004) Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4:11-22.
15. Dhodapkar MV, et al. (2003) A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 197:1667-1676.
16. Spisek R, et al. (2007) Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med 204:831-840.
17. Dhodapkar MV, Krasovsky J, Olson K (2002) T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells. Proc Natl Acad Sci USA 99:13009-13013.
18. Diefenbach A, Raulet D (2002) The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 188:9-21.
19. Groh V, Steinle A, Bauer S, Spies T (1998) Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells. Science 279:1737-1740.
20. Bauer S, et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-729.
21. Wu J, et al. (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730-732.
22. Ogasawara K, Lanier LL (2005) NKG2D in NK, T cell-mediated immunity. J Clin Immunol 25:534-540.
23. Gonzalez S, Groh V, Spies T (2006) Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol 298:121-138.
24. Groh V, et al. (1996) Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 93:12445-12450.
25. Groh V, et al. (1999) Broad tumor-associated expression and recognition by tumor-derived gd T cells of MICA and MICB. Proc Natl Acad Sci USA 96:6879-6884.
26. Girlanda S, et al. (2005) MICA expressed by multiple myeloma and monoclonal gammopathy of undetermined significance plasma cells costimulates pamidronate-activated gammadelta lymphocytes. Cancer Res 65:7502-7508.
27. Carbone E, et al. (2005) HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 105:251-258.
28. Gasser S, Orsulic S, Brown EJ, Raulet DH (2005) The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436:1186-1190.
29. Jamieson AM, et al. (2002) The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17:19-29.
30. Diefenbach A, et al. (2000) Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1:119-126.
31. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH (2001) Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-171.
32. Cerwenka A, Baron JL, Lanier LL (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98:11521-11526.
33. Smyth MJ, et al. (2005) NKG2D function protects the host from tumor initiation. J Exp Med 202:583-588.
34. Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738.
35. Salih HR, Rammensee HG, Steinle A (2002) Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169:4098-4102.
36. Groh V, Smythe K, Dai Z, Spies T (2006) Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity. Nat Immunol 7:755-762.
37. Wu JD, et al. (2004) Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 114:560-568.
38. Kaiser BK, et al. (2007) Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature 447:482-486.
39. Jinushi M, Hodi FS, Dranoff G (2006) Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci USA 103:9190-9195.
40. Bartkova J, et al. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434:864-870.
41. Gorgoulis VG, et al. (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434:907-913.
42. Alter G, Malenfant JM, Altfeld M (2004) CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294:15-22.
43. Kyle RA, et al. (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356:2582-2590.
44. Groh V, et al. (2005) Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci USA 102:6461-6466.
45. Castriconi R, et al. (2003) Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100:4120-4125.
46. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV (2002) Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 195:125-133.
47. Richardson PG, Mitsiades C, Hideshima T, Anderson KC (2006) Bortezomib: Proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57:33-47.
48. Zhang YW, et al. (2005) Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway. Mol Cell 19:607-618.
49. Okazaki IM, Kotani A, Honjo T (2007) Role of AID in tumorigenesis. Adv Immunol 94:245-273.
50. Gourzi P, Leonova T, Papavasiliou FN (2006) A role for activation-induced cytidine deaminase in the host response against a transforming retrovirus. Immunity 24:779-786.
51. Rebmann V, et al. (2007) Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients. Clin Immunol 123:114-120.